1. European Urology Oncology
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers 
Nieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, Evan Y. Yu, Ajjai S. Alva, Simon J. Crabb, Thomas Powles, Jonathan E. Rosenberg, Jack Baniel, Ulka N. Vaishampayan, Dominik R. Berthold, Sylvain Ladoire, Syed A. Hussain, Matthew I. Milowsky, Neeraj Agarwal, Andrea Necchi, Sumanta K. Pal, Cora N. Sternberg, Joaquim Bellmunt, Matthew D. Galsky, Lauren C. Harshman 
European Urology Oncology 
DOI: /j.euo
Copyright © Terms and Conditions

2. Fig. 1
Most frequently administered chemotherapeutic regimens in the neoadjuvant setting with the corresponding adjuvant therapy. Each line represents one patient's pathway. Carbo=carboplatin; ddMVAC=dose-dense methotrexate-vinblastine-adriamycin-cisplatin; GC=gemcitabine-cisplatin; MVAC=methotrexate-vinblastine-adriamycin-cisplatin.
European Urology Oncology DOI: ( /j.euo )
Copyright © Terms and Conditions

3. Fig. 2
Time to relapse (TTR) in patients with adverse residual disease (ypT3–4 and/or ypN+) despite neoadjuvant chemotherapy based on adjuvant chemotherapy use. (A) Patients with ypT3–4 and/or ypN+ residual disease. (B) Patients with ypT4b and/or ypN+ residual disease. Kaplan-Meier curves represent crude survival estimates. AC=adjuvant chemotherapy; NAC=neoadjuvant chemotherapy; Obs=observation. aMultivariable analyses were adjusted for pathological stage (stage III and stage IV disease), type of NAC (cisplatin based, carboplatin based, and other regimens), and age.
European Urology Oncology DOI: ( /j.euo )
Copyright © Terms and Conditions

4. Fig. 3
Overall survival (OS) by use of adjuvant chemotherapy. Kaplan-Meier curves represent crude survival estimates. AC=adjuvant chemotherapy; NAC=neoadjuvant chemotherapy; Obs=observation. aMultivariable analyses were adjusted for pathological stage (stage III and stage IV disease), type of NAC (cisplatin-based and carboplatin-based and other regimens), and age.
European Urology Oncology DOI: ( /j.euo )
Copyright © Terms and Conditions